Bacteriophage Therapy for the Prevention and Treatment of Fracture-Related Infection Caused by Staphylococcus aureus: a Preclinical Study

Onsea, Jolien; Post, Virginia; Buchholz, Tim; Schwegler, Hella; Zeiter, Stephan; Wagemans, Jeroen; Pirnay, Jean‐Paul; Merabishvili, Maya; D’Este, Matteo; Rotman, Stijn G.; Trampuž, Andrej; Verhofstad, Michael H J; Obremskey, William T.; Lavigne, Rob; Richards, R. Geoff; Moriarty, T. Fintan; Metsemakers, Willem‐Jan

doi:10.1128/spectrum.01736-21

Cited by 30 publications

(14 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Basic phage research and its applications are intensively pursued worldwide ( 1 ). For the nontraditional treatment of infections caused by Staphylococcus aureus strains, which belongs to the ESKAPE pathogen group with increasing multidrug resistance ( 2 ), the most convenient phages for therapeutic application are lytic bacteriophages of the genus Kayvirus ( 3 – 6 ). These bacteriophages are effective therapeutic agents for the treatment of severe infections with multidrug-resistant staphylococci ( 7 ).…”

Section: Introductionmentioning

confidence: 99%

Global Transcriptomic Analysis of Bacteriophage-Host Interactions between a Kayvirus Therapeutic Phage and Staphylococcus aureus

Finstrlová

Mašlaňová

Reuter³

et al. 2022

Microbiol Spectr

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Global Transcriptomic Analysis of Bacteriophage-Host Interactions between a Kayvirus Therapeutic Phage and Staphylococcus aureus

Finstrlová

Mašlaňová

Reuter³

et al. 2022

Microbiol Spectr

View full text Add to dashboard Cite

show abstract

“…As a potential antibacterial agent, phages can effectively and specifically infect host bacteria ( Onsea et al., 2021 ). Nonetheless, phages often have distinct biological characteristics such as host range, proliferation rates, temperature and pH stability, which altogether limit the industrial production of phage preparations ( Cai et al., 2019 ).…”

Section: Introductionmentioning

confidence: 99%

Isolation and Characterization of vB_kpnM_17-11, a Novel Phage Efficient Against Carbapenem-Resistant Klebsiella pneumoniae

Bai

Zhang

Liang

et al. 2022

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Phages and phage-encoded proteins exhibit promising prospects in the treatment of Carbapenem-Resistant Klebsiella pneumoniae (CRKP) infections. In this study, a novel Klebsiella pneumoniae phage vB_kpnM_17-11 was isolated and identified by using a CRKP host. vB_kpnM_17-11 has an icosahedral head and a retractable tail. The latent and exponential phases were 30 and 60 minutes, respectively; the burst size was 31.7 PFU/cell and the optimal MOI was 0.001. vB_kpnM_17-11 remained stable in a wide range of pH (4-8) and temperature (4-40°C). The genome of vB_kpnM_17-11 is 165,894 bp, double-stranded DNA (dsDNA), containing 275 Open Reading Frames (ORFs). It belongs to the family of Myoviridae, order Caudovirales, and has a close evolutionary relationship with Klebsiella phage PKO111. Sequence analysis showed that the 4530 bp orf022 of vB_kpnM_17-11 encodes a putative depolymerase. In vitro testing demonstrated that vB_kpnM_17-11 can decrease the number of K. pneumoniae by 105-fold. In a mouse model of infection, phage administration improved survival and reduced the number of K. pneumoniae in the abdominal cavity by 104-fold. In conclusion, vB_kpnM_17-11 showed excellent in vitro and in vivo performance against K. pneumoniae infection and constitutes a promising candidate for the development of phage therapy against CRKP.

show abstract

“…Investigations into the use of phage therapy for musculoskeletal infections are sparse; most of the knowledge coming from the Eliava Institute of Bacteriophages, Microbiology and Virology (Tbilisi, Georgia). Metsemakers is involved in multiple research projects on the topic of implant-related infections and reported a rising number of studies/instances in recent years [ 18 , 19 , 20 ]. They are the head of the care program for musculoskeletal infections and of the Coordination Group for Bacteriophage Therapy, Leuven, affiliated with Leuven University Hospitals.…”

Section: Scientific Sessionsmentioning

confidence: 99%

Foundation of the Belgian Society for Viruses of Microbes and Meeting Report of Its Inaugural Symposium

Łątka

Aertsen

Boeckaerts

et al. 2023

Viruses

Self Cite

View full text Add to dashboard Cite

The Belgian Society for Viruses of Microbes (BSVoM) was founded on 9 June 2022 to capture and enhance the collaborative spirit among the expanding community of microbial virus researchers in Belgium. The sixteen founders are affiliated to fourteen different research entities across academia, industry and government. Its inaugural symposium was held on 23 September 2022 in the Thermotechnical Institute at KU Leuven. The meeting program covered three thematic sessions launched by international keynote speakers: (1) virus–host interactions, (2) viral ecology, evolution and diversity and (3) present and future applications. During the one-day symposium, four invited keynote lectures, ten selected talks and eight student pitches were given along with 41 presented posters. The meeting hosted 155 participants from twelve countries.

show abstract

Bacteriophage Therapy for the Prevention and Treatment of Fracture-Related Infection Caused by Staphylococcus aureus: a Preclinical Study

Cited by 30 publications

References 52 publications

Global Transcriptomic Analysis of Bacteriophage-Host Interactions between a Kayvirus Therapeutic Phage and Staphylococcus aureus

Global Transcriptomic Analysis of Bacteriophage-Host Interactions between a Kayvirus Therapeutic Phage and Staphylococcus aureus

Isolation and Characterization of vB_kpnM_17-11, a Novel Phage Efficient Against Carbapenem-Resistant Klebsiella pneumoniae

Foundation of the Belgian Society for Viruses of Microbes and Meeting Report of Its Inaugural Symposium

Contact Info

Product

Resources

About